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Hematoma formation and inflammation occurs during the beginning stages of fracture 
repair, which require the presence of innate cells such as macrophages. Macrophages are 
subdivided into proinflammatory, M1, or anti-inflammatory, M2, phenotypes with different 
functions, cytokine profiles, and surface markers. In this study, in vitro and in vivo models were 
used to deplete M1 macrophages, using Mac-1 Sap conjugated antibody (Mac1SAP), to 
determine the effects on fracture healing. In vitro study, primary macrophages isolated from 
mice femoral bone marrow were harvested and differentiated into M1 macrophages (+LPS), M2 
macrophages (+IL-4), or undifferentiated then treated with either vehicle or 10pM Mac1SAP. 
Primary macrophages and media were collected at days 2 and 5 post Mac1SAP treatment for 
flow cytometry and cytokine quantification. For the in vivo model, mice were treated with 
Mac1SAP prior to fracture. Bone marrow was then harvested from femurs on days 2 and 4 post- 
fracture for flow cytometry and cytokine quantification. MicroCT, trichrome staining, SAFO 
staining was used to evaluate the bone repair process. Immunohistochemistry was also 
performed using iNOS to identify M1 macrophages and Arg-1 to identify M2 macrophages 
within the fracture callus. FACS and IHC results demonstrated that Mac1SAP decreased the M1 
macrophage population while protein multiplexing showed significant changes in cytokine 
expression profiles both in vitro and in vivo.  MicroCT and histology data demonstrated that 
Mac1SAP treatment impaired bone healing. Overall, the data suggest that depletion of M1 





Fracture repair relies on cellular and molecular interactions and can take months to years 
to fully resolve (Marsell and Einhorn, 2011). The repair process involves four main stages 
including: inflammation, soft callus formation, hard callus formation, and bone remodeling 
(Schindeler et.al. 2008; Cottrell et.al, 2016). Each of these stages require different types of cells 
and cellular interactions to allow for proper union of the fractured bone. A microenvironment 
made of cells and proteins navigate the fracture healing process. For example, a hematoma 
contains a hypoxic microenvironment full of cells such as platelets, leukocytes, and 
mesenchymal stem cells that release growth factors such as transforming growth factors (TGFs), 
fibroblast growth factor (FGF), and vascular endothelial growth factors (VEGFs) and cytokines 
such as tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), IL-6, and granulocyte-colony 
stimulating factor (G-CSF) (Shui et.al, 2017). 
Directly following a fracture, the vasculature within the bone is disrupted. A fibrin 
network that builds around the fracture causes the formation of a hematoma. Hematoma 
formation coincides with an influx of leukocytes such as neutrophils and macrophages (Loi et.al, 
2017). Neutrophils are one of the first cells recruited to the fracture (Loi et.al, 2017; Claes et.al, 
 
2012, Bastian et.al, 2016). Besides being the first responder to the fracture, neutrophils have 
other functions including secreting chemokines for the recruitment of macrophages (Claes et.al, 
2012). Bastian found that in human fractures, neutrophil counts within the hematoma were 
highest within the first 3 days following the fracture and macrophages were the next group of 
cells present in the fracture sample (Bastian et.al, 2016). Both neutrophils and macrophages, are 
key immune cells in the inflammatory stage of the healing process. McCauley found that 
following a fracture, isolated murine femoral bone marrow contains both macrophages and 
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dendritic cells and the highest number of dendritic cells were found at day 2 post-fracture 
(McCauley et.al, 2020). 
In addition to the leukocytes that are present, there are other key modulators of 
inflammation that play a significant role in the development of the inflammatory response. These 
modulators are cytokines which provide a pro-inflammatory or anti-inflammatory environment. 
Examples of cytokines that are present in a hematoma include IL-1β, IL-6, IL-8, IL-10, IL-12, 
monocyte chemoattractant protein (MCP), macrophage colony-stimulating factor (M-CSF), and 
TNF-α (Walters et.al, 2017). Together the cytokines and immune cells make up the 
inflammatory response of a fracture. 
 
Callus formation following a fracture, involves a completely different set of mechanisms 
at the site of the fracture. The major players during this stage of repair are chondrocytes and 
fibroblasts that create a soft callus for mechanical support of the fracture (Schindeler et.al, 2008). 
These cell types will aide in the production of cartilage necessary for the callus. In addition to 
the cells, there are growth factors, collagens, and bone morphogenetic proteins (BMPs) present 
within the microenvironment of the fracture site (Gerstenfeld et.al, 2003). 
 
Hard callus formation is responsible for osteogenesis which is achieved by the high 
activity of osteoblast as well as the continual use of BMPs (Schindeler et.al, 2008; Gerstenfeld 
et.al, 2003). Another important part of this phase includes tissue angiogenesis which requires 
VEGF to regain the vasculature disrupted during fracture (Gerstenfeld et.al, 2003). The final 
stage of fracture healing response is bone remodeling which allows for the bone to be restored 
to the cortical structure that it contained prior to the induction of a fracture (Schindeler et.al, 
2008). This phase entails a balance of anabolic and catabolic activity of the osteoblast and 
osteoclasts (Einhorn and Gerstenfeld, 2015). Following this stage, the bone is back to the 
original structure and considered completely healed. 
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While all the stages of fracture healing are important, any type of atypical response can 
result in a delayed union or nonunion of the fracture due to improper healing of the fracture. 
Studies have found that when the inflammatory response is altered, changes occur in the 
healing cascade which results in improper healing. NOD/scid-Il2Rγc
null mice lack functional 
monocytes, dendritic cells, natural-killer cells, and mature lymphocytes and therefore are 
experience severe lack of innate and adaptive immune system (Rapp et.al, 2016). Using these 
mice, Rapp found that endochondral ossification was delayed in these immunodeficient mice 
compared to a set of immunocompetent control mice of the same age (Rapp et.al, 2016).  In 
another study, Yang found that IL-6 null mice displayed delayed callus formation and bone 
remodeling compared to 
wildtype mice (Yang et.al, 2007), indicating the important role of cytokines during the 
beginning phases of the fracture healing. Another study used C57BL/6 mice and treated them 
with either daily systemic injection of lipopolysaccharide (LPS) or saline to determine the effect 
of systemic inflammation on bone healing (Behrends et.al, 2017). This study determined that the 
systemic inflammatory response impaired the quality of bone regenerated in mice femurs which 
was associated with the impaired revascularization in the tissue (Behrends et.al, 2017). These 
studies demonstrate the importance of a properly balanced immune response during fracture 
repair. 
Macrophages are an important component to the inflammatory stage of a fracture 
response. However, there are many types of macrophages that are present in tissue at distinct 
times and have different effector functions. Under homeostatic conditions, tissues have resident 
macrophages present but during inflammation immune macrophages are recruited to promote an 
inflammatory response and/or regulate wound healing (Wu et.al, 2013). Within bone, the 
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resident tissue macrophages are known as osteal macrophages and help maintain skeletal 
homeostasis by working alongside with osteoblasts to regulate bone formation (Sinder et.al, 
2015), underscoring the delicate balance between the immune system and bone. 
 
Macrophages of the inflammatory response can differentiate between two main subtypes, 
a process known as polarization, M1-classically activated macrophages and M2- alternatively 
activated macrophages (Wu et.al, 2013; Martinez and Gordon, 2014; Horwood, 2016). M1 and 
M2 macrophages require different types of stimulus, contain different surface markers, and 
secrete different combinations of cytokines (Martinez and Gordon, 2014; Shapouri-Moghadddai 
et.al, 2018). Based on effector functions, M1 macrophages are classified as pro-inflammatory 
while the M2 macrophages are classified as anti-inflammatory (Shapouri-Moghaddai et.al, 
2018). M2 macrophages can further be subdivided into M2a, M2b, M2c, and M2d each with 
distinct functions (Wu et.al, 2013; Shapouri-Moghaddai et.al, 2018). M1 macrophages are 
known to secrete proinflammatory cytokines such as TNF-α, IL-1β, IL-6, and IL-12 while M2 
macrophages secrete anti-inflammatory cytokines such as IL-10 and transforming growth 
factor-β (TGF-β) (Shapouri-Moghaddam et.al, 2018).
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Figure 1: Macrophage polarization between M1 and M2 macrophage (Saqib et al., 2018). Figure 
demonstrates different factors that can drive the macrophage polarization to become the M1 or 
M2 macrophage phenotype. General functions of both the M1 and M2 macrophage are listed in 
the corresponding boxes.
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Evidence that macrophages have a unique ability to polarize between the different 
subtypes in response to immune response (Jagunin et.al, 2013). One study used B6D2/J and 
C57BL/6J mice and isolated bone marrow-derived macrophages and to expose to cytokine 
treatments of IFN-γ, IL-12, IL-4, or IL-10 then activated by LPS to determine how the cytokine 
environment shifts the cytokines being expressed by the bone marrow-derived macrophages 
(Stout et.al, 2005).  This study showed that the when the macrophages are exposed to different 
cytokines the functionality of the macrophages can switch their phenotype becoming more pro- 
inflammatory or anti-inflammatory (Stout et.al, 2005). McCauley found that regarding fracture 
repair, the amount of M2 macrophages in the bone marrow decreases during the acute 
inflammatory response while the amount of M1 macrophages increase at this time in the repair 
process (McCauley et.al, 2020). This demonstrates the importance of M1 macrophages during 
the inflammatory stage of fracture healing. 
The concept of macrophages polarizing between pro-inflammatory and anti-inflammatory 
states is very important in the balance of inflammation. Without this concept of regulation there 
may exist a state of chronic inflammation which would negatively affect the healing process 
(Claes et.al, 2012). Therefore, it is important that M1 macrophages are present in the 
inflammatory stage of the fracture healing response to generate the pro-inflammatory 
environment needed to kick-off the repair while the presence of M2 macrophage are more vital 
to being in the later stages of the repair process such as hard callus formation and bone 
remodeling (Wu et.al, 2013; Schlundt et.al, 2018). A balance of macrophage subtypes in a 
microenvironment is essential for proper union of a fracture. 
Previous studies that examined the functionality of macrophages in fracture healing 
typically use a clodronate liposome as a method for depletion which broadly deplete macrophage
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population regardless of the subtype (Lin and O’Connor, 2016; Schlundt et.al, 2018). The 
liposome works by targeting the phagocytic functionality of the macrophages to ingest the 
clodronate that the liposome contains which leads to the apoptosis of the cell (van Rooijen and 
Kesteren-Hendrikx, 2003). Therefore, not only are the clodronate liposome dangerous to all 
macrophages but also to any type of phagocytic cell that can be in contact with the liposome 
such as neutrophils and dendritic cells. The CD11b surface marker is important to macrophage 
functionality in an inflammatory situation by allowing macrophages to enter a site of 
inflammation (Podolnikova et.al, 2016). With this role, CD11b is important for a pro- 
inflammatory response and is used to characterize M1 macrophage population (Cucak et.al, 
2013). The purpose of this study is to examine the role of M1 macrophages during fracture 
healing response by depleting CD11b+ cells and observing changes to macrophage subtypes, 
cytokine profiles, and bone formation. 
Materials and Methods 
 
Animals model and Fracture 
 
Adult Swiss Webster mice (Taconic Farms, Germantown, NY) were used.  Mice were 
anesthetized using 0.01 mg/g body weight of ketamine and xylazine. One week prior to the 
fracture, mice underwent a procedure for insertion of an intramedullary pin to stabilize the 
fracture. The fracture was done on the right femur using a custom-made, three-point impactor 
(BBC Specialty Automotive Center, Linden, NJ). Both the fractured femur as well as the 
contralateral femur of each animal was collected. All experimental procedures were approved by 
Rutgers New Jersey Medical School Institutional Animal Care and Use Committee. 
Isolation of Bone Marrow Derived Macrophages (BMDM)
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Media used for isolation and culturing of BMDM consisted of 1x Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1% penicillin and 
streptomycin, 1% glutamine and 20% conditioned L929 media. In a syringe with a 27.5 gauge 
needle, 1mL of media was used to flush the bone marrow. Femurs that were collected were 
teased away of any remaining muscle or tissue. The heads of the femurs were sliced off using a 
scalpel. Using forceps, the syringe that inserted into the bone marrow and expelled the complete 
growth media. The bone was rotated half-way through the flushing process to expel more of the 
bone marrow from the other end of the femur. All of the contents of the bone marrow were 
collected into a 15 mL falcon tube that was kept on ice and the bone was discarded into the 
biohazard. The bone marrow was spun down for 1 minute at 500 rpm to remove any larger 
pieces of debris like bone or muscle. Following that spin, the supernatant was transferred to a 
new 15 mL falcon tube. This was spun down again at 1,000 rpm at 4°C for 10 minutes to pellet 
cells. Supernatant made of the media was collected and stored at -20°C for further analysis while 
the pellet was resuspended in 2mL of media and placed on a 60mm plate. 
Differentiation of Cells into Macrophages Subtypes and MacSAP1 Treatment 
 
Once the primary macrophages were grown to confluency on the 6-well plate, LPS was 
used at concentration of 1 ng/mL to differentiate the cells into LPS-induced M1 macrophages 
while IL-4 (Peprotech, Rocky Hill, NJ) was used at concentration of 10ng/mL to differentiate the 
cells into IL-4-induced M2 macrophages. Mac-1 conjugated antibody (Mac1SAP) (Advanced 
Targeting Systems, San Diego, CA) was used at three different doses 0pM, 5pM, 10pM, and 
20pM to deplete the CD11b+ population of cells. The results of the dose-response showed that 
 
10pM was effective at depleting the CDllb+ population and this dose was used for the remaining 
in vitro experiments (data not shown).  24hr after the addition of the LPS, the corresponding
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concentrations of the Mac1SAP was added to the appropriate wells. At 48 hours, the media was 
replenished without adding back in Mac-1 treatment. At 24 hours, 48 hours, and 72 hours after 
addition of the Mac1SAP treatment, media was collected and stored at -20°C for cytokine 
analysis and cells were prepared for flow cytometry. This was repeated for the IL-4 induced M2 
macrophages. 
Characterization of Macrophage subtypes 
 
Cells were collected from 60mm petri dishes by scraping methods and counted using a 
hemocytometer. 5x105 cells in media suspension were brought up to 1mL of FACS buffer and 
spun down for 4 minutes at 1000 rpm at 4°C to pellet the cells. Supernatant was aspirated off. To 
prevent nonspecific binding, 10µL of FBS was used for blocking. The samples were incubated 
for 10 minutes at 4°C. An antibody mixture was made of MHC class II FITC (Miltenyi, Bergisch 
Gladbach, Germany), CD11b APC (Miltenyi, Bergisch Gladbach, Germany), CD86 PE Vio770 
(Miltenyi, Bergisch Gladbach, Germany), F4/80 PerCP Vio 700 (Miltenyi, Bergisch Gladbach, 
Germany), and CD40 APC Vio770 (Miltenyi, Bergisch Gladbach, Germany)  at a dilution of 
1:200 with FACS buffer. 100µL of the antibody mixture was added to each of the samples. One 
sample was excluded from having the antibody mixture to serve as a blank negative control. All 
the samples were covered and left to stain in the dark for 20 minutes. After the staining, 200 µL 
of the FACS buffer was used to dilute the cell suspension sample. Samples were then run on 
MacsQuant Flow Cytometer (Miltenyi Biotech, Auburn, CA). Data as analyzed using FlowJo 
software (BD, Ashland, OR). 
Cytokine Quantification 
 
Using a mouse cytokine magnetic multiplex assay kit (Millipore Sigma, Darmstadt, Germany), 
 
standards and controls were prepared according to manufacturer’s instruction. On a 96-well
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microliter plate, 200 µL of wash buffer was added into each well and incubated on a plate shaker 
for 10 minutes. Contents of the wells were decanted out of the black. In the appropriate wells, 
25µL of standards and control was added along with 25µL of the assay buffer. In the wells that 
contain the background, standards, and controls, 25µL of media used to culture macrophages 
was added. The samples were vortexed and then 25µL of the sample was added to the unknown 
wells in biological replicates. In each well, the mixed combination of all the cytokines were 
added to the wells with 25µL. The plate was wrapped in foil and incubated on the plate shaker 
overnight at 4°C. Using a magnet, the contents of the well was decanted and 200µL of wash 
buffer was added and placed on a plate shaker for 30 seconds. The plate was placed back on the 
magnet and the contents were decanted and this wash process was repeated. In each well, 25µL 
of the detection antibodies was added and the plate was covered with foil and incubated on a 
plate shaker for 1 hour at room temperature. Then, 25µL of Streptavidin-Phycoerythrin to each 
well and the plate was covered and incubated on a plate shaker for 30 minutes at room 
temperature. The plate was washed with the wash buffer twice. Lastly, 150µL of the MAGPIX 
drive fluid was added to each well and the solution was resuspended on a plate shaker for 5 




Fractured bone was decalcified, embedded into paraffin, sliced, placed onto a microscope slide 
by histology core at Rutgers University-Newark. Samples of fractured bone then went through 




Slides prepared from histology core at Rutgers University-Newark were placed into the 
desiccator for 2 days to allow for any moisture to be removed between the tissue and the 
microscope slide. Tissue went through a series of solution washes for deparaffinization and 
rehydration as follows: xylene for 5 mins, 3x; 100% ethanol for 5 mins, 2x; 95% ethanol for 2 
mins, 2x; 70% ethanol for 2 mins,2x;  50% ethanol for 2 mins, 2x; and finally deionized water 
for 2 mins, 2x. Slides were then placed into a heated solution of 10mM sodium citrate buffer (pH 
 
6.0) for 3 hours at 70°C. Slides were left on a benchtop to cool for 3 minutes to room 
temperature. During the cooling, a hydrophobic barrier pen was used to draw barrier around the 
tissue. Slides were washed 3x for 5 minutes with deionized water before undergoing a 
peroxidase treatment of 100µL of 3% hydrogen peroxide for 15 mins. Slides were rinsed in PBS 
before being washed in PBS for 2mins for 2x. After the washes, 100µL of 3% SuperBlockTM 
Blocking Buffer (Thermo Scientific, Rockford, IL) solution was incubated for 5 mins before 
washing in 3x PBS for 30secs. 
All antibody staining was completed in a humidified chamber.  Primary antibodies iNOS 
(Novus, Centennial, CO), Arginase-1 (Novus, Centennial, Co), and F4/80 (Novus, Centennial, 
CO) were applied to each tissue sample and incubated. After the overnight incubation, the slides 
were washed 3x for 5 mins in PBS. Then each tissue section was stained with POLINK-2 PLUS 
Rabbit Antibody enhancer (IHC World, Woodstock, MD) at room temperature.  After rinsing 
twice for 2 mins in PBS, slides were stained with POLINK-2 PLUS Polymer HRP (IHC World, 
Woodstock, MD) for 10 mins at room temperature. The slides were then washed 3x for 2 mins in 
PBS. Diaminobenzidine (DAB) solution (Thermo Scientific, Rockford, IL) was then added to 
each slide which incubates at room temperature for 10 mins. The slides were washed for 2 mins 
in deionized water. Then hematoxylin (IHC World, Woodstock, MD) was applied to the slide to
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stain for 1 min. The stain was washed for 2 mins in deionized water. Slides were dehydrated 
using increasing concentrations of alcohol and xylene washes. Slides were mounted and viewed 
via light microscopy on an Accu-scope EXI-310 Trinocular Inverted Microscope (Accu-Scope 
Inc, Commack, NY). Slides were imaged at 40x magnification using Excelis™ HD camera 
(Accu-scope Inc, Commack, NY). 
MicroCT 
 
Fractured mice femurs were collected. Using established methods, µCT was preformed on 
 




Data was analyzed using SigmaPlot software (SyStat Software, San Jose, California). 
Appropriate student t-test, one-way, and two-way analysis of variance (ANOVA) was used for 
the sets of data along with post-hoc tests. 
Results 
 
I. Primary macrophages differentiated with LPS increased the M1 macrophage population but 
addition of Mac1SAP treatment decreased the M1 macrophage population. 
 
Flow cytometry analysis was completed to determine macrophage cell populations present in 
primary macrophages isolated from bone marrow of murine femurs after treatment. Figure 2 
demonstrates the gating strategy utilized for this study by providing an example data from the 
fracture and primary macrophage study. Figure 2A shows the gating for the CD11b+ population. 
Figure 2B demonstrates the gating strategy for identifying the M1 and M2 macrophage subtypes. 
Surface markers used to identify M1 macrophages include F4/80+/MHC class II+/CD86+/CDllb+ 
while M2 macrophages were identified as being F4/80+/MHC class II-/CD86-/CDllb-.
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Figure 2:  Gating Strategy for Analysis of Macrophage Cell Populations.  A) CDllb+/- 
populations histograms are shown at for Day 2 and Day 4 post-fracture. The Mac1SAP panel 
shown depletion of Cdllb+ cells at both day 2 and 4 post fracture.  B) Representative FACS plots 
are shown untreated primary macrophages (top) and LPS group (bottom) after 48 hours. The 
cells identified within the bracketed area are identified as F480+/CD86+/MHCII+. From this 
selected region 96.3% (top) and 93.8% (bottom) are also CDllb+. M2 macrophages are identified 
as F4/80+ cells that are negative for MHCII and CD86 (Q1) and are not CDllb+.
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The normalized CD11b+ population did not have any significant differences at 48hr post- 
treatment. At 120hrs post-treatment, there was a 56% decrease in the amount of CD11b+ cells in 
the LPS/Mac1SAP treated cells compared to the LPS treated cells (P <0.001, Figure 3A).  The 
LPS/Mac1SAP also showed a 66% decrease in the population size from 48hr to 120hr post- 
treatment (P <0.001, Figure 3A). IL-4 and IL-4/Mac1SAP treatment groups did not demonstrate 
a significant difference at either 48hr and 120hr post-treatment. 
 
The normalized M1 macrophage population was defined by using the strategy mentioned 
in the methods. At 120hr, the LPS/Mac1SAP group contained a significant 69% decrease 
compared to the LPS group (P=0.012, Figure 3B). Mac1SAP treatment significantly increased 
the M1 population compared to all the other treatment groups at 120hr post-treatment (P<0.001, 
Figure 3B).  Specifically, the Mac1SAP group had 59%, 87%, 71%, and 67% more M1s that 
LPS, LPS/Mac1SAP, IL-4, and IL-4/Mac1SAP populations, respectively (Figure 3B). 
The normalized M2 macrophage population was defined by using the strategy mentioned 
in the methods. At 120hr, Mac1SAP treatment group had a significantly lower M2 population 
than the rest of the treatment groups (P<0.001). More specifically, Mac1SAP group had a 73% 
decrease in M2 macrophages compared to LPS, 35% decrease compared to LPS/Mac1SAP, 57% 
decrease compared to IL-4, and 72% decrease compared to IL-4/Mac1SAP (Figure 3C). The 
LPS/Mac1SAP demonstrated a 59% decrease in the M2 macrophage population compared to the 
LPS population (P<0.001, Figure 3C). IL-4/Mac1SAP treatment group had a 34% increase in the 




Figure 3. Quantification of Macrophage Cell Type Post MacSAP Treatment. A) Cdllb+ 
Population at 48 and 120 hours post MacSAP treatment.  B) M1 Population at 120 hours post 
MacSAP treatment C) M2 Population at 120 hours post MacSAP treatment.
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II. Differentiation and Treatment of primary macrophages changed the cytokine expression 
profile. 
To detect the differences in the cytokine expression, xMAP analysis was performed on 
primary macrophages derived from the bone marrow of murine femurs. The cytokine 
concentrations for 48hrs post-treatment are represented in Tables 1 and concentrations for 120hrs 
post-treatment are represented in Table 2. Two-way ANOVA analysis demonstrated IL-4, IL-10, 
IL-13, KC, MCP-1, RANTES, TNF-α, M-CSF, IL-6, IP-10, LIX, G-CSF, MIP1α, IL-17, MIP1β, 
IL-2, IL-9, IL-5, MIG, IL-1α, IL-12p70, Eotaxin, IL-1β, LIF, GM-CSF, and IL-15 had 
significant differences between treatment groups (Table 3).  Principal component analysis 
demonstrated the relatedness between the cytokines to the macrophage subtype for the primary 
macrophage samples (Figure 4). 
IL-4 treated groups had significant increases in IL-4 concentration compared to vehicle, 
Mac1SAP, LPS, and IL-4/Mac1SAP (1537-fold, 166-fold, 12-fold, and 6-fold, respectively, 
P<0.001) independent of timepoint.  When analyzing the 48hr timepoint, the LPS/Mac1SAP 
group had significant increases in IL-4 concentration when compared to vehicle (1492-fold, 
P<0.001), Mac1SAP (161-fold, P<0.001), LPS (12-fold, P<0.001), and IL-4/Mac1SAP (6-fold, 
P<0.001), respectively.  The IL-4/Mac1SAP group also had significant increases compared to 
vehicle (260-fold, P=0.036) and Mac1SAP (28-fold, P=0.039).  At 120hr post-treatment, IL-4 
groups had significantly higher concentrations of IL-4 compared to Mac1SAP (163-fold, 
P<0.001), LPS/Mac1SAP (142-fold, P<0.001), and vehicle (59-fold, P<0.001). The IL- 
4/Mac1SAP group also had significantly higher concentrations of IL-4 compared to Mac1SAP 
(P<0.001) by 836-fold increase, LPS/Mac1SAP (P<0.001) by 1087-fold increase, LPS (P<0.001) 
by 836-fold increase, and vehicle (P<0.001) by 448-fold increase.
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IL-10 levels were also significantly different between treatment groups at both 48hr and 
 
120hr. At 48hrs, the LPS group had at least 6-fold higher concentrations of IL-10 compared to all 
other treatment groups (P<0.001). The IL-4/Mac1SAP group had a 4-fold significant increase in 
IL-10 when compared to vehicle (P<0.001), Mac1SAP (P<0.001), LPS/Mac1SAP (P<0.001), 
and IL-4 (P<0.001). At 120hr, the LPS group had at least a 2-fold higher significant increase 
when compared to IL-4 (P<0.001), IL-4/Mac1SAP (P<0.001), LPS/Mac1SAP (P=0.003), and 
Mac1SAP (P=0.004) groups. 
IL-13 levels were only found to be significantly different between treatment groups at 
 
48hrs post-treatment. LPS treated group had a significant increase in IL-13 concentration 
compared to vehicle (1.8-fold, P<0.001), Mac1SAP (1.7-fold, P<0.001), and LPS/Mac1SAP 
(1.3-fold, P=0.024) groups.   LPS/Mac1SAP treated group had significant increases in IL-13 
concentration compared to vehicle (1.4-fold, P=0.002) and Mac1SAP (1.3-fold, P=0.019) 
groups. IL-4 treated group had a significant increase in IL-13 concentration compared to vehicle 
 
(1.6-fold, P<0.001) and Mac1SAP (1.4-fold, P<0.001) treated groups, respectively. IL- 
 
4/Mac1SAP treated group had significant increase in IL-13 concentration compared to vehicle 
 
(1.6-fold, P<0.001) and Mac1SAP (1.4-fold, P<0.001). 
 
KC levels had significant differences between treatment groups at both 48hr and 120hr 
post-treatment. At 48hrs post-treatment, LPS had significant increases in KC concentration 
compared to all other treatment groups. LPS group increased 586-fold (P<0.001) compared to 
Mac1SAP, 283-fold compared to IL-4 (P<0.001), 234-fold compared to the vehicle (P<0.001), 
66-fold compared to LPS/Mac1SAP (P<0.001), and 1.2-fold increase compared to IL- 
 
4/Mac1SAP (P=0.038).  IL-4/Mac1SAP group increased 493-fold increase (P<0.001) when 
compared to Mac1SAP, 238-fold (P<0.001) when compared to IL-4 group, 197-fold when
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compared to vehicle  (P<0.001) and 55-fold when (P<0.001) compared to LPS/Mac1SAP. At 
 
120hr post-treatment, the LPS group had significant increases in KC expression compared to IL- 
 
4/Mac1SAP, IL-4, LPS/Mac1SAP, and Mac1SAP treated groups (P<0.001). LPS group was 3- 
fold higher than IL-4/Mac1SAP and IL-4 treated groups, 1.8-fold higher than the LPS/Mac1SAP 
group and 1.5-fold higher than the Mac1SAP group. The vehicle group was higher than IL- 
4/Mac1SAP group by 2.8-fold (P<0.001), IL-4 group by 4-fold (P<0.001), LPS/Mac1SAP group 
by 1.7-fold (P<0.001), and Mac1SAP group by 1.4-fold (P=0.001).  The Mac1SAP group had a 
2-fold increase when compared to IL-4/Mac1SAP (P<0.001) and IL-4 (P=0.001) groups. 
 
MCP-1 concentrations were significantly different between treatment groups at 120hrs. 
The vehicle group contained significant higher concentrations of MCP-1 compared to all other 
treatment groups (P<0.001). Mac1SAP group was 4.1-fold higher than LPS/Mac1SAP group 
(P<0.001), 3.8-fold higher than IL-4/Mac1SAP treatment (P<0.001) and 3.0-fold higher than IL- 
4 treatment (P<0.001). LPS significantly increased MCP-1 concentrations when compared to 
LPS/Mac1SAP treatment (3.4-fold, P=0.002), IL-4/Mac1SAP (3.0-fold, P=0.003), and IL-4 (2.4- 
fold, P=0.009). 
RANTES concentration were significantly different between treatment groups at both 
 
48hr and 120hr post-treatment. At 48hr post-treatment, LPS had 171-fold, 135-fold, 59-fold, and 
 
1.2-fold increase compared to Mac1SAP, vehicle, LPS/Mac1SAP, IL-4/Mac1SAP were found to 
be statistically different (P<0.001).  IL-4/Mac1SAP treatment had a higher RANTES 
concentration compared to Mac1SAP (139-fold, P<0.001), vehicle  (109-fold, P<0.001), IL-4 
(80-fold, P<0.001), and LPS/Mac1SAP (47-fold, P<0.001). At 120hr post-treatment, LPS 
 
treatment caused a 29-fold, 28-fold, and 3.8-fold higher concentration compared to IL-4, IL- 
 
4/Mac1SAP, Mac1SAP, respectively. RANTES concentration in the vehicle group was 25-fold
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higher than IL-4 treatment (P<0.001), 2.4-fold higher than IL-4/Mac1SAP treatment (P<0.001), 
 
3.3-fold higher than Mac1SAP treatment (P<0.001), and 1.4-fold higher than LPS/Mac1SAP 
treatment (P=0.028). LPS/Mac1SAP treated group had significantly higher concentration of 
RANTES compared to IL-4 (P<0.001), IL-4/Mac1SAP (P<0.001), and Mac1SAP (P=0.006) by 
17-fold, 16-fold, and 2.3-fold, respectively. Mac1SAP treatment was a 7.3-fold increase in 
 
RANTES concentration compared to IL-4/Mac1SAP (P=0.049). 
 
TNF-α concentration was significantly different between treatment groups at both 48hr 
and 120hr post-treatment. At 48hr post-treatment, LPS increased TNF-α 99-fold, 96-fold, 73- 
fold, 70-fold, and 1.4-fold higher when compared to vehicle, Mac1SAP, IL-4, LPS/Mac1SAP, 
IL-4/Mac1SAP treatment, respectively. TNF-α concentration was significantly higher in the IL- 
4/Mac1SAP treatment compared to vehicle  by 80-fold (P<0.001), to Mac1SAP by 77-fold 
(P<0.001), to IL-4 by 59-fold (P<0.001), and LPS/Mac1SAP by 57-fold (P<0.001). At 120hr 
post-treatment, vehicle  group had significantly higher concentration compared to IL- 
4/Mac1SAP (P<0.001), IL-4 (P<0.001), LPS/Mac1SAP (P<0.001), and Mac1SAP (P<0.001) by 
 
8.8-fold, 7.9-fold, 3.6-fold, and 2-fold, respectively. TNF-α concentration was significantly 
higher in LPS treated group compared to IL-4/Mac1SAP by 6.7-fold (P<0.001), IL-4 by 6-fold 
(P<0.001), and LPS/Mac1SAP by 2.7-fold (P<0.001). Mac1SAP treatment caused a significant 
increase in TNF-α concentration compared to IL-4/Mac1SAP treated group by 4.4-fold 
(P=0.003) and IL-4 treated group by 4.0-fold (P=0.004). 
M-CSF levels were significantly different between treatment groups at both 48hr and 
 
120hr post-treatment. At 48hr post-treatment, LPS group increased 1.7-fold compared to vehicle 
(P<0.001), 1.6-fold compared to vehicle (P<0.001), a 1.5-fold compared to LPS/Mac1SAP 
(P=0.003), and  1.4-fold compared to IL-4 (P=0.004). IL-4/Mac1SAP treatment had a
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significantly higher M-CSF concentration compared to vehicle by 1.5-fold (P=0.006) and 
compared to Mac1SAP by 1.4-fold (P=0.011). At 120hr, LPS treatment group was 1.2-fold 
higher in M-CSF concentration compared to both IL-4 (P=0.008) and IL-4/Mac1SAP (P=0.023). 
IL-6 was significantly different between treatment groups at both 48hr and 120hr post- 
treatment. At 48hr post-treatment, LPS group increased 488-fold, 480-fold, 307-fold, 224-fold, 
and a 2-fold compared to vehicle, MAC1SAP, IL-4, LPS/Mac1SAP, and IL-4/Mac1SAP, 
respectively (P<0.001). IL-4/Mac1SAP concentration of IL-6 was significantly higher than the 
vehicle (241-fold, P<0.001), Mac1SAP treated group (237-fold, P<0.001), IL-4 (152-fold, 
P<0.001), and LPS/Mac1SAP (111-fold, P<0.001) treatment group. At 120hr post-treatment, 
LPS treated group concentration of IL-6 was significantly higher compared to all other treatment 
groups (P<0.014). 
IP-10 concentration has significant differences between treatment groups at both 48hr 
and 120hr post-treatment. At 48hr post-treatment, LPS treated group had a significant increase 
compared to all other treatment group (P<0.001). At 120hr post-treatment, vehicle had 
significantly higher IP-10 concentration compared to all other treatments (P<0.001). The vehicle 
group was 22-fold higher than IL-4 and IL-4/Mac1SAP, 6-fold higher than LPS/Mac1SAP, 2.1- 
fold higher than Mac1SAP, and 1.8-fold higher than LPS treatment. LPS treated group had 
significantly higher concentration of IP-10 compared to IL-4 (P<0.001), IL-4/Mac1SAP 
(P<0.001), and LPS/Mac1SAP (P=0.002) by 1.2-fold, 12-fold, and 1.8-fold increases, 
respectively. Mac1SAP treatment had a 10-fold increase compared to both IL-4 (P<0.001) and 
IL-4/Mac1SAP (P<0.001) treatments. 
 
LIX concentration was significantly difference between treatment groups at 48hr post- 
treatment. The LPS group increased 4.8-fold, 4.6-fold, 3.8-fold, and 3.7-fold when compared to
21  
LPS/Mac1SAP, vehicle, Mac1SAP, and IL-4 (P<0.001), respectively. IL-4/Mac1SAP had 
significant differences in LIX concentration compared to Mac1SAP, vehicle, LPS/Mac1SAP, 
and IL-4 (P<0.008). 
MIP-1α concentration has significant differences between treatment groups at both 48hr 
and 120hr post-treatment. At 48hr post-treatment, LPS had significantly higher concentrations of 
MIP-1α compared to all other treatment groups (P<0.001). IL-4/Mac1SAP treatment group had 
significantly higher concentrations of MIP-1α at 48hr post-treatment when compared to IL-4 
(224-fold, P<0.001), vehicle  (212-fold, P<0.001), LPS/Mac1SAP (184-fold, P<0.001), and 
Mac1SAP (126-fold, P<0.001). At 120hr post-treatment, the vehicle group significantly 
increased in MIP-1α concentration compared to all treatment groups except LPS treatment 
(P<0.001). The LPS group increased in MIP-1α compared to IL-4/Mac1SAP, IL-4, 
LPS/Mac1SA, and Mac1SAP by 158-fold, (P<0.001), 101-fold (P<0.001), 5.9-fold (P<0.001), 
and 2.1-fold (P=0.003), respectively. Mac1SAP treated group was significantly higher in the 
MIP-1α concentration compared to IL-4/Mac1SAP by 74-fold (P=0.001) and IL-4 by 47-fold 
(P=0.009). 
IL-17 concentration were significantly different between treatment groups at both 48hr 
and 120hr post-treatment. At 48hr, the LPS group had significant differences in concentration 
compared to all other treatment groups (P<0.001). IL-4/Mac1SAP treatment significantly 
increased concentrations of IL-17 approximately 1.3-fold compared to Mac1SAP, vehicle, 
LPS/Mac1SAP, and IL-4 groups (P<0.008). At 120hr post-treatment, LPS treatment significantly 
increased IL-17 concentration when compared to IL-4 by 1.4-fold (P=0.001), IL-4/Mac1SAP by 
1.3-fold (P=0.01), and LPS/Mac1SAP by 1.25-fold (P=0.049).
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MIP-1β concentration was significantly different between treatment groups at both 48hr 
 
and 120hr post-treatment. At 48hr, LPS treatment had significantly higher concentrations of 
 
MIP-1β compared to all other treatment groups (P<0.001).  The highest increases occurred when 
the LPS group was compared to vehicle (245-fold, P<0.001), IL-4 (225-fold, P<0.001), 
LPS/Mac1SAP (211-fold, P<0.001), and Mac1SAP (189-fold, P<0.001). IL-4/Mac1SAP 
treatment caused a significantly higher concentration of MIP-1β compared to vehicle, IL-4, and 
Mac1SAP (P<0.001). At 120hr post-treatment, the vehicle group had significantly higher 
concentrations of MIP-1β compared to all other treatment groups (P<0.001). LPS treatment also 
caused a significantly higher concentration compared to IL-4/Mac1SAP (128-fold, P<0.001), IL- 
4 (70-fold, P<0.001), LPS/Mac1SAP (10-fold, P<0.001), and Mac1SAP (1.8-fold, P<0.001). 
Mac1SAP treatment had significant increase in MIP-1β concentration compared to IL- 
4/Mac1SAP (71-fold, P<0.001), IL-4 (39-fold, P<0.001), and LPS/Mac1SAP (5.6-fold, 
P<0.001). 
IL-2 concentration was significantly different between treatment groups at 48hr post- 
treatment. LPS treatment had significantly higher concentrations of IL-2 compared to vehicle 
(1.6-fold, P<0.001) and Mac1SAP (1.5-fold, P<0.001). The IL-4/Mac1SAP group significantly 
increased in IL-2 concentration compared to vehicle by 1.6-fold (P<0.001) and Mac1SAP 
treatment by 1.4-fold (P=0.001). IL-4 and LPS/Mac1SAP treatments were significantly higher in 
 
IL-2 concentration compared to vehicle by 1.4-fold (P=0.021) and 1.3-fold (P=0.025). 
 
IL-9 concentration was significantly different between treatment groups at 48hr post- 
treatment. LPS group had a 1.5-fold and 1.4-fold increase in IL-5 concentration compared to 
vehicle (P<0.001) and Mac1SAP (P<0.001) groups. LPS group also had a 1.2-fold increase 
compared LPS/Mac1Sap (P=0.009). IL-4/Mac1SAP group had significantly higher
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concentrations of IL-9 compared to vehicle (P=0.004) and Mac1SAP (P=0.008) groups. IL-4 
treatment caused a 1.4-fold increase in IL-9 compared to vehicle (P=0.023) and Mac1SAP 
(P=0.033). 
IL-5 concentration had significant differences between treatment groups at both 48hr and 
 
120hr post-treatment. At 48hr post-treatment, LPS treatment caused at least a 1.2-fold increase in 
IL-5 concentration compared to vehicle, Mac1SAP, and LPS/Mac1SAP.  IL-4/Mac1SAP 
treatment also caused an 1.3-fold increase in IL-5 concentration compared to vehicle  (P=0.004) 
and Mac1SAP treatment (P=0.008) while IL-4 treatment caused an 1.3-fold increase when 
compared to the vehicle  (P=0.012) and Mac1SAP (P=0.019) groups. At 120hr post-treatment, 
vehicle group had a 1.2-fold increase in IL-5 concentration compared to IL-4 (P=0.032). 
MIG concentration had significant differences between treatment groups at both 48r and 
 
120hr post-treatment. At 48hr post-treatment, LPS treatment had a 1.6-fold increase in MIG 
 
concentration compared to vehicle (P<0.001) and Mac1SAP (P<0.001). LPS treatment was also 
 
1.4-fold higher than LPS/Mac1SAP treatment (P=0.015). IL-4/Mac1SAP treatment caused a 1.4- 
fold increase in MIG concentration compared to vehicle (P=0.014) and Mac1SAP (P=0.02). At 
120hr, vehicle group had a 1.3-fold increase in MIG concentration compared to IL-4 (P=0.018) 
 
and LPS/Mac1SAP (P=0.048). 
 
IL-1α concentration had significant differences between treatment groups at both 48hr 
and 120hr post-treatment. At 48hr post-treatment, LPS treatment group had significant increase 
in IL-1α concentration compared to vehicle , Mac1SAP, LPS/Mac1SAP, and IL-4 by 7.6-fold 
(P<0.001), 7.1-fold (P<0.001), 6.1-fold (P<0.001), and 5.8-fold (P<0.001), respectively. IL- 
4/Mac1SAP treatment caused significant increases in IL-1α compared to vehicle (5-fold, 
P=0.003),  Mac1SAP (4.6-fold, P=0.003), LPS/Mac1SAP (4-fold, P=0.005),  and IL-4 (3.8-fold,
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P=0.005). At 120hr post-treatment, LPS group increased by at least 3.9-fold when compared to 
IL-4, IL-4/Mac1SAP, vehicle, and Mac1SAP (P<0.001).  LPS/Mac1SAP treatment had 
significantly higher concentration of IL-1α compared to IL-4, IL-4/Mac1SAP, vehicle , and 
Mac1SAP by 3.4-fold (P=0.022), 3.2-fold (P=0.027), 3-fold (P=0.030), and 2.9-fold (P=0.031), 
respectively. 
IL-12p70 concentration had significant differences between treatment groups at 48hr 
post-treatment. LPS significantly increased in IL-12p70 concentration by a 1.4-fold or higher 
when compared to vehicle or Mac1SAP (P<0.001). IL-4/Mac1SAP treated group have a 1.3-fold 
increase in IL-12p70 concentration compared to vehicle (P=0.015) and Mac1SAP (P=0.05). 
Eotaxin concentration had significant differences between treatment groups at 48hr post- 
treatment. LPS treatment had 1.3-fold or higher increase in concentration compared to vehicle 
(P=0.001), Mac1SAP (P=0.002) and LPS/Mac1SAP group (P=0.028). IL-4/Mac1SAP treatment 
had a 1.4-fold increase in concentration compared to vehicle (P=0.018) and Mac1SAP (P=0.025) 
treatment. 
IL-1β concentration had significant differences between treatment groups at 48hr post- 
treatment. LPS treatment had 1.3-fold or greater concentrations of IL1-β compared to Mac1SAP, 
vehicle, LPS/Mac1SAP, and IL-4 (P>0.009). IL-4/Mac1SAP treatment caused a 1.4-fold 




LIF concentration had significant differences between treatment groups at 48hr and 120hr 
post-treatment. At 48hr post-treatment, LPS treatment had a 2.4-fold increase in LIF 
concentration compared to the vehicle (P=0.05). At 120hr post-treatment, the vehicle group had a
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1.6-fold increase in LIF concentration compared to LPS/Mac1SAP (P=0.001). LPS treatment 
had a 1.5-fold increase in LIF concentration compared to LPS/Mac1SAP (P=0.011). 
GM-CSF concentration had significant differences between treatment groups at 48hr 
post-treatment. LPS treatment had 1.8-fold or higher concentration of GM-CSF compared to 
vehicle, Mac1SAP, IL-4, and LPS/Mac1SAP treatments (P<0.050).
 
 




Mean (pg/mL) ±STD 
Cytokine Vehicle Mac1SAP LPS LPS+Mac1SAP IL-4 IL-4+Mac1SAP 
IL-4 37.67±10.07 348.67±160.65 4796.33±5728.64 56188.33±2366.36 57913.50±734.02 9777.17±7553.27 
IL-10 25.67±1.16 27.33±2.31 183.17±41.78 29.17±1.76 31.33±4.04 111.33±5.13 
IL-13 10.33±0.58 11.33±0.58 18.83±0.76 14.83±0.29 16.33±2.08 16.33±0.58 
KC 117.83±85.32 47.17±9.57 27621.17±1760.19 418.83±303.09 97.50±87.93 23236.50±2265.85 
MCP-1 17.83±0.29 18.00±1.73 1800.67±734.56 30.33±5.03 31.67±5.69 647.00±146.54 
RANTES 71.17±20.04 56.00±7.21 9598.67±369.53 164.00±59.81 97.00±26.85 7769.83±1286.13 
TNF-α 55.00±2.00 56.50±5.22 5437.50±251.53 77.17±22.54 74.50±17.59 4375.00±421.63 
M-CSF 25.50±0.50 26.33±2.52 43.33±4.16 29.50±2.29 30.67±0.58 38.00±3.46 
IL-6 23.33±2.08 23.67±3.06 11375.33±4374.98 50.83±30.58 37.00±9.85 5621.17±830.58 
IP-10 55.67±5.77 56.83±10.68 1862.17±335.36 52.83±5.01 63.00±14.18 1176.00±158.36 
LIX 92.00±14.73 90.83±16.36 432.33±205.12 113.50±13.43 115.67±8.02 318.50±62.01 
G-CSF 43.83±8.43 38.33±4.16 13280.17±4006.41 85.33±59.88 48.17±18.48 7921.00±1276.71 
MIP1α 86.67±75.96 146.33±193.75 30171.61±5206.40 100.00±77.96 82.33±44.64 18406.17±2129.43 








MIP1β 57.00±11.27 73.67±32.58 13956.50±684.26 66.00±10.97 60.83±7.49 10931.33±505.80 
IL-2 14.00±1.00 15.33±1.53 23.00±3.61 18.83±0.76 19.00±1.00 22.00±1.73 
IL-9 14.00±1.00 14.33±0.58 23.50±3.28 17.67±1.53 19.83±1.61 22.33±2.52 
IL-5 17.67±1.16 18.00±1.00 25.83±2.36 20.67±0.58 22.67±0.58 23.33±1.53 
MIG 16.33±1.16 16.67±2.08 26.67±4.04 19.67±2.08 21.00±1.00 23.33±3.22 
IL-1α 21.67±0.58 23.00±2.65 163.83±63.37 27.00±1.73 28.33±1.53 106.83±33.21 
IL-12p70 20.00±1.00 21.00±2.65 29.33±3.22 23.50±1.50 25.33±2.08 26.50±2.18 
Eotaxin 18.00±1.00 18.33±1.53 27.33±4.04 20.67±2.08 21.83±1.44 25.17±3.33 
IL-1β 29.33±1.16 29.33±2.52 44.83±7.78 33.67±0.58 34.33±1.53 40.67±3.51 
LIF 19.00±0.50 19.67±2.08 45.50±10.90 21.00±1.73 24.33±1.53 32.33±2.89 
GM-CSF 15.17±0.29 16.00±1.00 44.00±20.42 24.17±7.15 21.67±2.89 27.83±8.78 
IL-15 25.67±4.16 30.33±5.86 37.00±4.36 29.17±2.47 31.67±2.52 32.17±1.44 
IL-7 34.00±1.73 40.67±4.04 42.83±4.93 36.33±3.22 41.33±1.61 38.50±3.28 
VEGF 73.83±9.75 77.67±34.12 336.17±63.90 88.50±26.84 88.17±27.05 184.67±49.24 
IL-12p40 51.50±5.22 56.00±27.21 57.67±5.51 50.17±7.29 55.00±4.58 57.33±5.03 
IL-3 34.50±3.04 38.67±3.79 42.67±4.93 37.33±6.66 38.00±0.00 36.17±2.26 














Mean (pg/mL) ±STD 
Cytokine Vehicle Mac1SAP LPS LPS+Mac1SAP IL-4 IL-4+Mac1SAP 
IL-4 355.00±317.53 127.50±4.77 190.17±42.31 146.33±18.15 20774.67±5656.38 159060.33±7227.30 
IL-10 69.50±2.18 41.17±7.65 87.83±13.16 40.00±13.08 30.83±0.76 31.67±4.04 
IL-13 17.17±2.57 16.67±1.53 16.67±1.12 15.33±1.53 15.00±0.00 16.00±1.00 
KC 21570.67±1267.88 15177.33±2194.03 22783.00±1295.37 12474.00±3921.14 8847.00±927.27 7715.33±2144.38 
MCP-1 12092.83±1607.19 5832.50±2637.00 4733.17±354.08 1411.33±713.13 1973.67±82.00 1555.17±704.07 
RANTES 3763.83±10.05 1146.17±601.36 4385.33±608.37 2598.50±355.17 151.17±18.06 157.67±80.23 
TNF-α 1779.83±188.13 900.33±387.76 1352.67±184.73 500.50±232.59 226.50±35.44 203.00±63.04 
M-CSF 58.67±4.94 55.33±3.79 62.50±6.95 53.34±2.52 49.83±0.76 51.33±6.66 
IL-6 937.50±88.42 275.67±165.05 5396.50±709.67 1157.00±744.90 63.33±7.23 58.17±7.52 
IP-10 1264.17±40.64 578.00±289.87 684.17±61.72 191.67±101.80 56.67±3.06 57.67±12.06 
LIX 246.50±49.76 144.83±57.27 237.00±24.98 133.17±14.89 106.00±4.27 107.17±14.36 
G-CSF 5754.00±1737.73 978.33±576.75 8236.00±576.75 8236.00±808.92 2667.67±749.79 88.00±17.11 
MIP1α 22453.00±4147.63 8126.33±5044.35 17392.83±2911.09 2953.83±3217.66 171.50±37.18 110.33±48.56 








MIP1β 10933.83±1628.68 4920.67±499.50 8841.67±571.24 882.67±639.74 125.67±62.98 69.33±1.61 
IL-2 23.17±3.25 20.67±1.53 22.00±1.00 20.67±0.58 19.00±0.00 20.50±1.32 
IL-9 23.00±3.61 20.67±1.53 23.00±1.00 20.67±1.12 18.67±2.08 20.33±2.31 
IL-5 26.00±3.61 22.67±1.61 24.33±0.58 23.00±1.00 21.00±0.00 23.33±1.53 
MIG 27.33±3.22 22.67±1.53 24.17±1.61 21.17±1.26 20.33±0.58 22.33±3.22 
IL-1α 32.50±3.50 33.67±3.51 130.33±18.48 97.33±40.53 28.33±1.16 30.67±3.06 
IL-12p70 27.00±3.46 24.33±0.58 25.67±0.57 24.33±1.16 24.00±1.00 25.00±1.73 
Eotaxin 24.33±4.04 23.33±2.31 23.67±0.76 22.17±2.75 21.00±1.00 22.00±1.73 
IL-1β 37.67±5.51 34.33±1.53 39.17±1.76 35.83±2.75 34.33±1.53 35.17±2.75 
LIF 99.67±9.02 85.00±13.45 92.83±15.12 61.67±13.14 83.67±4.93 76.17±19.25 
GM-CSF 21.17±3.01 19.33±2.52 20.67±0.58 23.83±0.29 17.67±1.04 19.67±1.53 
IL-15 30.00±4.09 20.33±1.15 32.33±1.53 28.00±0.00 28.00±1.00 30.50±2.78 
IL-7 41.50±2.18 36.50±3.78 39.17±2.57 35.33±1.53 37.00±0.00 40.67±6.11 
VEGF 28005.00±1918.33 27744.83±1599.29 28968.50±1616.65 23774.50±1484.46 28601.00±1843.80 26416.50±3715.42 
IL-12p40 50.00±7.21 46.17±6.17 55.17±4.91 60.17±6.53 51.33±3.22 55.00±7.21 
IL-3 39.17±4.54 37.17±0.76 39.00±2.00 37.67±2.89 36.00±0.00 40.33±5.86 









Table 3: xMAP Two Way ANOVA Analysis Summary of Primary Macrophage Treatment 
Groups overtime. 
 
Two-Way ANOVA analysis 
 
Cytokine Time Treatment Treatment x Time 
IL-4 <0.001 <0.001 <0.001 
IL-10 <0.001 <0.001 <0.001 
IL-13 <0.001 <0.001 <0.001 
KC <0.001 <0.001 <0.001 
MCP-1 <0.001 <0.001 <0.001 
RANTES <0.001 <0.001 <0.001 
TNF-α <0.001 <0.001 <0.001 
M-CSF <0.001 <0.001 <0.001 
IL-6 0.0020 <0.001 <0.001 
IP-10 0.1360 <0.001 <0.001 
LIX 0.1720 <0.001 <0.001 
G-CSF 0.1970 <0.001 <0.001 
MIP1α 0.5360 <0.001 <0.001 
IL-17 0.5960 <0.001 <0.001 
MIP1β 0.6070 <0.001 <0.001 
IL-2 0.0001 0.0010 <0.001 
IL-9 0.0020 0.0010 <0.001 
IL-5 0.0010 0.0020 <0.001 
MIG 0.0050 0.0030 <0.001 
IL-1α 0.7180 0.0001 0.0020 
IL-12p70 0.5940 0.0130 0.0030 






IL-1β 0.5270 0.0001 0.0070 
LIF 0.0001 0.0030 0.0160 
GM-CSF 0.0670 0.0050 0.0450 
IL-15 0.5490 0.0300 0.0710 
IL-7 0.6170 0.1840 0.0760 
VEGF 0.0001 0.0640 0.0810 
IL-12p40 0.4240 0.3640 0.2340 
IL-3 0.7910 0.4520 0.3710 


















































Figure 4: Principal Component Analysis for M1s, M2s, and cytokines of Primary Macrophages.  (A) component plot for analysis for 
three principal components, red dots depict cell subtypes and blue dots depict cytokines.  THE KON values for this analysis was 
0.544, Bartlett’s test of sphericity was <0.0001, and the three components explained 91.416% of the total variance.  (B) Pattern Matrix 









III. Mac1SAP treatment caused changes in the M1 and M2 macrophage at day 4 post-treatment 
for in vivo fracture model 
Flow cytometry was preformed and analyzed for the in vivo fracture model, to determine 
the differences in the cell populations of bone marrow derived macrophages. All the samples 
were normalized to the to the naïve samples. The normalized F4/80+ cell population did not 
show any significant differences in the vehicle and Mac1SAP treated groups at both day 2 and 4 
post-fracture (Figure 5A). At day 2 post-fracture, the Mac1SAP treatment had a significant 
decrease in the CD11b+ cell population compared to the vehicle treated group (P<0.05, Figure 
6B). Mac1SAP treated group had a 65% decrease when compared to the vehicle. At day 4 post- 
fracture, the Mac1SAP treated group displayed a 21% decrease in CD11b+ cell population 
compared to the vehicle (P<0.05, Figure 5B). 
For the normalized M1 macrophage population, there was not a significant difference in 
the treatment groups at day 2 post-fracture. However, at day 4 post-fracture the Mac1SAP group 
had 34% significantly less (P<0.050, Figure 5C) M1 macrophages when compared to the vehicle. 
At day 2 post-fracture, the Mac1SAP treated group displayed a 45% significant decrease in the 
amount of M2 macrophages compared to the vehicle group (P<0.050, Figure 5D). At day 4 post- 
fracture, the Mac1SAP treated group displayed a 30% decrease in the M2 macrophages 
compared to the vehicle treated group (P<0.050, Figure 5D).
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Figure 5: Comparison of F4/80+ cell, CDllb+, M1 and M2 cell populations after toxin treatment. 
Both graphs cell populations that are normalized to naïve.  Significance between treatment 
groups are noted. A) Normalized F4/80+ population post treatment in Days 2 and 4. B) 
Normalized CD11b+ population post treatment on Days 2 and 4. C) M1 D) M2.  Macrophage 
populations were normalized to the naïve samples. Significant Differences are noted between 
Treatment groups (P<0.050, one-way ANOVA)
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IV. Mac1SAP treatment prior to fracture changes the cytokine expression profile in vivo 
 
To detect changes in the cytokine expression, xMAP analysis was completed on in vivo 
fracture samples on naïve, days 2 and 4 post-fracture that were treated with Mac1SAP or the 
vehicle. All the data values and levels of significance are denoted in Table 4. Principal 
component analysis demonstrates the relatedness of cytokines to macrophage populations 
(Figure 6). Day 4 post-fracture vehicle treated samples had higher concentrations of IL-9 by 2.5- 
fold (P<0.001), LIF by 9.0-fold (P<0.001), IL-6 by 8.5-fold (P<0.001), LIX by 8.4-fold 
(P<0.001), VEGF by 4.7-fold (P=0.037), IL-2 by 4.5-fold (P<0.001), MIP-1β by 7.2-fold 
(P<0.001), KC by 6.5-fold (P=0.003), IP-10 by 3.3-fold (P=0.003), TNF-α by 7.0-fold 
(P<0.001), and IFN-γ by 8.0-fold (P<0.001) compared to naïve vehicle treated samples. 
Day 4 post-fracture Mac1SAP treated samples had higher concentrations of IL-9 by 4.5- 
fold (P<0.001), LIF by 13.5-fold (P<0.001), IL-6 by 14.6-fold (P<0.001), LIX by 6.2-fold 
(P<0.001), VEGF by 9.9-fold (P<0.001), IL-2 by 3.6-fold (P<0.001), MIP-1β by 4.9-fold 
(P<0.001), KC by 8.0-fold (P<0.001), IP-10 by 8.0-fold (P<0.001), TNF-α by 5.7-fold 
(P<0.001), MIG by 8.7-fold (P<0.001), and IFN-γ by 5.2-fold (P<0.001) compared to naïve 
Mac1SAP samples. 
Mac1SAP treatment at day 4 post-fracture had higher concentration of IL-9 by 1.8-fold 
(P<0.001), LIF by 2.1-fold (P<0.001), IL-6 by 2.7-fold (P<0.001), VEGF by 2.7-fold (P<0.001), 
IL-2 by 1.5-fold (P<0.001), KC by 2.0-fold (P<0.001), IP-10 by 3.6-fold (P<0.001), and MIG by 
12.5-fold (P<0.001) compared to vehicle treatment. 
 
Vehicle treatment at day 4-post fracture had higher concentrations of LIX by 1.4-fold 
(P<0.001), MIP-1β by 1.2-fold (P<0.001), TNF-α by 1.3-fold (P=0.002), and IFN-γ by 1.2-fold 
(P=0.001) compared to Mac1SAP treatment.
 
 
Table 4: xMAP Summary of Fracture Mac1SAP Treatment Overtime. 
 
 Mean (pg/mL) +-STD Two-Way ANOVA analysis 
    Naïve 2 Days 4 Days    
Cytokine Vehicle Mac1SAP Vehicle Mac1SAP Vehicle Mac1SAP Treatment Time Treatment 
x Time 
IL-9 52.17±10.03 54.13±8.78 51.50±6.61 46.67±4.51 131.25±21.41 242.00±35.16 <0.001 <0.001 <0.001 
LIF 17.67±2.34 25.00±10.86 35.67±14.84 31.83±4.19 159.00±53.78 338.00±51.03 <0.001 <0.001 <0.001 
IL-6 19.58±2.69 30.83±6.83 66.33±33.92 73.00±27.73 166.50±40.21 451.00±31.23 <0.001 <0.001 <0.001 
LIX 89.33±4.40 88.75±24.10 100.33±16.44 87.50±9.50 754.50±60.42 550.50±69.00 0.002 <0.001 <0.001 
VEGF 62.17±13.08 79.33±28.75 79.83±15.61 66.83±9.25 294.00±103.11 786.00±257.58 0.007 <0.001 0.002 
IL-2 25.17±4.71 47.00±15.56 33.67±8.96 30.33±9.02 112.50±13.30 169.50±36.78 0.011 <0.001 0.035 
MIP1β 34.50±3.08 41.50±7.85 41.17±1.61 39.33±1.53 249.75±16.13 202.00±24.98 0.026 <0.001 0.003 
KC 31.08±6.93 50.63±17.01 61.67±11.37 57.50±11.03 204.75±71.68 406.00±113.42 0.027 <0.001 0.021 
IP-10 74.25±19.52 113.63±39.56 133.17±48.23 110.34±14.05 252.00±10.39 906.00±470.07 0.038 0.002 0.026 
TNF-α 51.17±5.78 49.50±2.27 55.33±5.69 54.00±1.73 357.75±59.16 283.50±12.37 0.054 <0.001 0.030 
MIP2 19.58±2.50 23.25±2.36 22.83±1.61 22.33±1.53 108.00±4.90 124.50±15.00 0.064 <0.001 0.099 
MIG 242.00±202.48 210.63±31.37 170.00±131.94 135.67±55.77 145.50±81.15 1824.00±331.96 0.064 <0.001 0.099 















Figure 6: Principal Component Analysis for M1s, M2s, and cytokines of Bone Marrow Aspirates 
Post-Fracture.  (A) component plot for analysis for three principal components, red dots depict 
cell subtypes and blue dots depict cytokines.  The three components explained 90.648% of the 
total variance.  (B) Pattern Matrix for four principal component analysis which explains 95.373% 




V. MicroCT data shown significant differences in the bone healing at day 14 post-fracture 
 
MicroCT was performed on the vehicle and Mac1SAP treated femurs at day 14 post- 
fracture. This analysis included measurements of the bone mineral density, bone volume, 
trabeculae volume, trabecular thickness, and cortical area. 
Figure 7 shows the femur healing at day 14 post-fracture with the coronal and transverse 
planes of the femur. Table 5 summarizes the analysis of the microCT data. Vehicle and 
Mac1SAP treatment displayed significant differences in the bone volume (P=0.042). Mac1SAP 
treated group had a 514,012-fold decrease in the bone volume compared to the vehicle. In terms 
of trabeculae volume, Mac1SAP treated group had a 270,891-fold decrease compared to the 
vehicle (P=0.048). The trabecular thickness in the Mac1SAP treated group was 109-fold lower 
compared to the vehicle (P<0.001). The cortical area of the Mac1SAP group displayed an 8983- 
fold decrease compared to the vehicle (P=0.008). The bone mineral density and the ratio of bone 





Figure 7: MicroCT Analysis of Day 14 Mouse Femur Fracture Post Mac1SAP Treatment. A) 
Vehicle Treatment Group B) Mac1SAP Treatment Group; For both (Left) Coronal Plane (Right) 
Transverse Plane. Photo created by Jessica Cottrell. 
 









    Bone Mineral 
Density 
524.44±92.87 444.82±117.81 0.410 
Bone Volume 15029696.33±8823334.98 29.24±4.88 0.042 
Trabeculae 
Volume 
2692653.33±1661787.32 9.94±2.75 0.048 
BV/TV 44.660±3.830 62.120±23.449 0.272 
Trabecular 
Thickness 
16.120 ±2.728 0.148±0.00646 <0.001 






Table 5: Summary of Micro CT Analysis of Day 14 Mouse Femur Fracture Post Mac1SAP 
Treatment. The data were analyzed via Student’s t-Test.  Significant changes are noted in bold.
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To display the differences between the fracturing healing, SAFO and trichrome staining 
was performed on fractured femurs on both vehicle and Mac1SAP treated. The histology was 
performed at days 4, 7, and 14 post-fracture. SAFO staining did detect any significant 
differences in cartilage development at day 4 post-fracture but at day 7 post-fracture there 
appears be significantly more cartilage that development in the vehicle treated femur compared 
to the Mac1SAP treated (Figure 8A). Even in day 14 post-fracture there is more cartilage 
staining in the vehicle compared to the Mac1SAP treated femur. The trichrome staining does not 
show any major differences between the vehicle and Mac1SAP treated samples at days 4 and 14 
post-fracture. At day 7 post-fracture, the trichrome shows a larger, more defined callus in the 




Figure 8: Saffrain O fast green and trichrome staining of mouse femurs at days 4, 7, and 14 post 
fracture.  Vehicle (left) and Mac1SAP (right) treatment at days 4, 7, and 14 post-fracture in 
SAFO (A) and Trichrome (B) staining.
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VII. Immunohistochemistry reveals that the Mac1SAP reduces iNOS expression at day 4 post- 
fracture. 
Immunohistochemistry was performed to determine the amount and localization of the 
iNOS and Arg-1 expression in vehicle and Mac1SAP groups at day 4 post-fracture. For iNOS 
expression, Mac1SAP treatment caused a 58.9% significant decrease in the amount of iNOS+ 
cells per femur compared to the vehicle (P=0.029, Figure 10). However, Mac1SAP treatment did 




Figure 9: Immunohistochemistry Analysis of M1 iNOS and M2 Arg-1 markers at day 4 post- 
fracture in mouse femur. (A) Vehicle and Mac1SAP samples of the IHC at day 4 post-fracture 
with negative vehicle , iNOS, and Arg-1 staining. Arrows show positively stained cells. Images 
taken at 20X magnification (B) Mean cell counts for number of B) iNOS+ cells and (C) Arg-1 





Fracture repair starts with inflammation and hematoma formation and is critical for the 
repair process.  Inhibition, disruption, or dysregulation during inflammation negatively affects 
bone repair. An example of the impairment to bone repair was demonstrated by non-steroidal 
anti-inflammatory drugs (NSAIDs) when it inhibited cyclooxygenase isoenzymes to reduce 
inflammation and pain which negatively affected the fracture repair process (Cottrell & 
O’Connor, 2010). Inflammation provides a microenvironment of immune cells and cytokines 
that coordinate cell recruitment and function which supports the stages of bone repair.  The 
purpose of this study was to better understand the functional role of M1 macrophages during the 
acute inflammatory phase of fracture healing.  The functional importance of M1 macrophages 
was explored using two different inflammation models, an in vitro study which utilized primary 
macrophages isolated from bone marrow of murine femurs and in vivo study that used fractured 
mice femurs. Both models used Mac1SAP toxin to deplete the M1 cell population during an 
inflammatory response and measured cytokine expression profiles.  For the in vivo study, 
histology, immunohistochemistry, and microCT data were also examined to determine if 
Mac1SAP depletion impaired fracture healing. 
Mac1SAP depletion, in both the in vitro and in vivo models, took approximately 4-5 days 
to effect macrophage populations.  The delayed effect is likely a result of the Mac1SAP 
mechanism of action.  Once it gains entrance into a cell it inhibits the ribosomal function and 
then blocks protein production.  On day 2, primary macrophages and in vivo fracture bone 
marrow isolates did not contain any significant differences in the M1 macrophage population 
when vehicle and Mac1SAP depleted samples were compared. However, primary macrophages 
and the fractured samples had significantly lower M1 macrophages by day 5 and 4, respectively.
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Immunohistochemical analysis also shows significantly less iNOS expression in the callus of 
 
Mac1SAP-treated animals compared to vehicle-treated controls. 
 
Mac1SAP treatment in vivo does not only affect the M1 macrophage population. When 
treated with Mac1SAP, the M2 macrophage population experiences a significant decrease 
compared to the vehicle at days 2 and 4 post-fracture. This change may be attributed to 
Mac1SAP depletion polarizing several M2 macrophages toward the M1 macrophage phenotype 
to compensate for the loss of M1 macrophages. Italiani and Borashi support this hypothesis in 
their research by proposing that M2 macrophages are more commonly polarized towards the M1 
phenotype (Italiani & Boraschi, 2014). McCauley also demonstrates that M2 macrophages can 
polarize from M2 macrophages to M1 macrophages by the increase of the ratio of M1/M2 
macrophages during the inflammatory phase of the fracture (McCauley et al., 2020).  Our data 
supports this hypothesis because Mac1SAP depletion does not reduce the number of F4/80+ 
population, which denotes all types of macrophages, instead Mac1SAP depletion appears to 
promote polarization between subtypes. However, treatment of Mac1SAP changed not only the 
macrophage subtypes but the cytokine profiles as well. Cytokines that are involved in M1/M2 
macrophage polarization were affected by the Mac1SAP treatment, such as IL-6. This cytokine 
has been shown to be involved in macrophage polarization (Yin et al., 2018). IL-6 was 
upregulated when treated with Mac1SAP compared to the vehicle in the in vivo fracture samples 
indicting that macrophage polarization was occurring. In addition to the polarization process, the 
chemokines involved in recruiting macrophages were affected by the Mac1SAP treatment. 
Chemokines are more closely associated to the M1 macrophages compared to the M2 
macrophage population in both the in vitro and in vivo models. Chemokines are important for the 
recruitment and polarization of macrophages during inflammation (Xuan et al., 2015). MIP-1β is
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an example of an important chemokine that was negatively affected when treated with 
Mac1SAP. Studies have been shown that macrophages upregulate MIP-1β secretion following 
exposure to LPS in vivo (Sherry et al., 1998). Our data correlates well with this study, LPS- 
treated primary macrophages showed increased concentrations of MIP-1β but cotreatment with 
LPS/Mac1SAP significantly decreased its concentration.  Similarly, in vivo samples treated with 
Mac1SAP reduced MIP-1β when compared to vehicle at day 4 (Table 4). Since the depletion of 
M1 macrophages altered the concentration, it is likely that there is a relationship between the 
amount of M1 macrophages in the sample and the MIP-1β concentration. Another chemokine 
that is affected by Mac1SAP treatment in the in vivo fracture study was KC. This chemokine had 
a higher concentration in the Mac1SAP treatment compared to the vehicle.  KC is known to play 
a major role in the recruitment for neutrophils (Filippo et al., 2008). This upregulation of the 
chemoattractant for neutrophils in the Mac1SAP treatment could be a way that the immune 
system is compensating for the lack of M1 macrophages by pulling other cells that are able to 
produce an inflammatory response. A possible reason why this same chemokine trend was not 
seen in the in vitro samples is because KC is secreted by tissue macrophages which were not 
cultured. Therefore, our in vitro system may not able to mimic the same response as the in vivo 
study (Flippo et al., 2008). Furthermore, McCauley et al. found that LIF had a correlation with 
dendritic cells during the inflammatory response of a fracture (McCauley et al., 2020). Like KC, 
in the in vivo samples LIF was seen to be upregulated when exposed to the Mac1SAP. 
Therefore, LIF may be important to the recruitment of dendritic cells to help with the 
inflammatory response to offset the depletion of the M1 macrophages. Dendritic cells have been 
demonstrated to polarize into M2 macrophages in the presence of IL-6 (Chomarat et al., 2000). 
The increase in LIF and IL-6 in the in vivo system show that dendritic cells are moving to the
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inflammatory site with the ability to differentiate into macrophages to make up for the effects of 
the Mac1SAP on the macrophage populations. Overall, these chemokines are linked to M1 
macrophages by either being positively or negatively affected by the population of M1 
macrophages present. 
Proinflammatory cytokines are closely related to each other and more closely associated 
with M1 macrophages. Using a multivariant analysis that compares the cytokines and 
macrophages types, the proinflammatory cytokines were grouped together. These cytokines 
include IL-1α, IL-1β, IL-6, and TNF-α. It is expected that the proinflammatory cytokines are 
closely associated with M1 macrophages compared to the M2 macrophages. M1 macrophages 
secrete and respond to proinflammatory cytokines to develop a robust inflammatory response at 
the site of inflammation, such as a fracture (Wermuth & Jimenez, 2015). This result is expected 
based on the known data that shows that the proinflammatory cytokines such as IL-1, IL-6, and 
TNF-α are present during the early stages following a fracture (Mountziaris & Mikos, 2008). 
TNF-α plays an important role of the fracture healing process. Without TNF-α, fracture healing 
is impaired because of the role that this cytokine has in recruitment of mesenchymal stem cells 
and apoptosis of hypertrophic chondrocytes which are important effector functions during the 
inflammatory stage (Gerstenfeld et al., 2003).  However, overexpression of TNF-α causes excess 
inflammation that can negatively affect fracture healing by causing a reduction in cartilage and 
impairing bone mineralization (Timmen et al., 2014). This data demonstrates the importance of 
regulation of TNF-α expression during the fracture healing process. Results from our in vitro 
study showed LPS/Mac1SAP treatment caused a decrease in concentration of TNF-α compared 
to the LPS treated samples. The in vivo study demonstrated similar results with Mac1SAP 
treatment causing a decrease in TNF-α compared to the vehicle. In these samples, the
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proinflammatory signals from the TNF-α are lacking because of the depletion of M1 macrophage 
that the Mac1SAP causes. The decrease in the TNF-α concentration may be indirectly related to 
other cytokine activity such as IL-9, which was upregulated in the Mac1SAP treated samples. IL- 
9 has been shown to upregulate TGF-β which caused a decrease in TNF-α expression (Pilette et 
al., 2002). 
Of the cytokines tested none were associated to the M2 macrophage population in either 
the in vitro or in vivo studies. Interestingly, this means that anti-inflammatory cytokines were 
more correlated early on with the state of M1 macrophages. These anti-inflammatory cytokines, 
such as IL-4 and IL-10, are often linked to M2 macrophage secretions because of the regulatory 
function of M2 macrophages (Mantovani et al., 2013). In the in vitro study, IL-10 concentration 
was increased when treated with LPS but decreased when treated with LPS/Mac1SAP. This 
change in concentration may be because of the decrease in the M2 macrophage population with 
the LPS/Mac1SAP treatment. However, this change of IL-10 is not observed in the in vivo study. 
The treatment of Mac1SAP causes the polarization of M2 macrophages to the M1 phenotype and 
incidentally caused a decrease in the M2 population, which may not be the only cell type that 
secreted IL-10 in the fracture microenvironment. Other cells such as mast cells, neutrophils, 
eosinophils, and dendritic cells are all capable of producing IL-10 which could be compensating 
for the lower M2 macrophage population (Iyer & Cheng, 2012). Therefore, the anti- 
inflammatory cytokine, IL-10, was not shown to be affected in the in vivo study by the change in 
macrophage population from the treatment of Mac1SAP. 
Bone fracture healing is disrupted in Mac1SAP treated samples compared to vehicle. 
Normally when fracture healing occurs in murine model it lasts for about 28 days with a soft 
callus forming on day 7.  As the cartilage develops, the hard callus matures into woven bone by
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day 14 (Marsell & Einhorn, 2011). On day 7 Mac1SAP treated calluses are larger callus then 
vehicle as seen with the trichrome staining (Figure 9). However, SAFO staining demonstrates 
that vehicle-treated samples have significantly more cartilage then Mac1SAP-treated samples. 
MicroCT analysis shows that by day 14, there is more bone volume present in the vehicle-treated 
fracture with a more developed callus compared to the Mac1SAP treatment. Together, these 
results demonstrate that the Mac1SAP treated samples are impaired in the fracture healing 
process compared to the vehicle treated fracture. Changes to the pro-inflammatory markers such 
as TNF-α may play an important role in disrupting the healing process. Gerstenfeld et al. found 
that TNF-alpha signaling plays an important role for the bone repair and without the signaling 
the fracture repair is impaired (Gerstenfeld et al., 2001). Therefore, depletion of the M1 
macrophage population and/or changes is the cytokine expression response may both contribute 
to negative affects seen on fracture healing. 
A future direction for this study would be including more timepoints. By including more 
timepoints, it could lead to a better understanding of how the macrophage population is affected 
by the Mac1SAP treatment before day 2 post-fracture and after day 4 post-fracture. Starting the 
timepoints before the treatment of Mac1SAP could provide information on the macrophage 
subtype composition prior to the knock down and map out exactly how long it takes for the 
knock down of the M1 macrophage population. The current data from the in vivo study has 
shown that most of the effects occur by day 4 post-fracture but there could be earlier effects that 
have not been observed because the study only compares two timepoints.  Extending the time 
points past day 4 post-fracture could provide information on how long it would take for the 
composition of the macrophage population to return to the levels like that in the vehicle samples. 
This would give an idea of how long the effects of the Mac1SAP treatment would last before the
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M1 macrophage and M2 macrophage populations could potentially recover. Another direction 
for the in vivo study could be to mimic it with a genetic model. Mac1SAP treatment targeted 
CD11b+ cells, however this is method could negatively affect other cell populations. CD11b 
marker can be found on other myeloid cells besides macrophages, such as neutrophils (Lishko et 
al., 2018). Therefore, using a genetic model to target M1 macrophages could potentially 
eliminate the risk of affecting other cells. 
This study was important to understanding the effect of the M1 macrophages have during 
the inflammatory stage of the fracture repair process. Understanding the way that specific cell 
populations function in the repair process, could help when the immune system is compromised 
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